Looks like the front load to this promo
Everyone,
and Welcome to our new subscribers,
If there was ever an alert to get excited about its definitely this one as it offers a potential solution for millions of people around the world who are suffering from the many different types of cancer.
Over recent decades, the incidence of cancer has escalated to epidemic proportions, now striking nearly one in two men (44%) and more than one in three women (39%). This increase translates into approximately 56% more cancer in men and 22% more cancer in women over the course of a single generation.
Despite dramatic advances in our understanding of cancer cell biology, conventional cancer therapy has remained fundamentally unchanged for decades. The three major forms of cancer therapy remain to be surgery, radiation and chemotherapy. Surgery and radiation therapies have reached their logical limits, and chemotherapy remains the current mainstay of cancer management.
Immunovative, Inc. (NASDAQ OTCBB: IMUN) offers a new modality for cancer treatment, which holds great promise for becoming a curative therapy with minimal toxicity that works together with or replaces current treatment methods. The human immune system is capable of seeking out and destroying cancers cells wherever they reside in the body. Harnessing the power of the immune system holds the greatest potential for winning the battle against cancer.
IMUN's concept is called the Mirror Effect™. In the Mirror Effect™, T-cells from a normal donor are infused into a patient and instead of these foreign cells mediating the GVT effect, these cells instead stimulate the patient’s own immune system to attack the tumor. This effect is known as the host-vs-tumor (HVT) effect and it is the mirror image of the GVT effect. The patient’s immune system is alerted by the infusion of foreign cells and raises up to reject the foreign cells, an effect known as host-vs-graft (HVG). The HVG effect is the mirror image of the GVH effect. However, unlike the GVH effect the HVG effect is not toxic to a patient.
The reason that the GVT effect is such a powerful immune mechanism for curing cancers is that the interaction between the host and donor creates the release of an array of inflammatory cytokines that signal the body of an imminent danger. These danger signals shut down the ability of the tumor to avoid an immune attack and enable immune-mediated killing of tumors disseminated throughout the body. The Mirror Effect™ creates these same danger signals in the context of a rejection response to a foreign cell infusion (HVG) rather than as an attack against normal tissues (GVH). Thus the Mirror Effect™ has the potential to cause a proven curative anti-tumor effect of BMT without the extremely toxic side-effects. This represents a new concept in the treatment of cancer.
Protocols are being developed for patients with the following indications:
Breast
Colorectal
Gall Bladder
Squamous Cell
Ovarian
Pancreas
Sarcoma
Lung
Esophageal
Prostate
Bladder
IMUN currently has 2 products Allostim & Allovax.
IMUN is establishing potential partnerships for developments and commercialization of its immunotherapy products:
• AlloStimTM
Phase I/II - Refractory chronic lymphocytic leukemia
Phase I/II - Bladder cancer
Phase I/II - HIV/AIDS
• AlloVaxTM
Phase I/II – Recurrent glioblastoma Brain cancer
Phase I/II – Child leukemia Melanoma
Phase I/II – Head & Neck cancer
DEVELOPMENT PARTNERS INCLUDE:
•University of Colorado
•Mayo Clinic
•University of Arizona
•University of California
Recently we've seen numerous biotechnology stocks putting on huge gains with the likes of ARNA, OREX, VVUS, & PCYC soaring hundreds of percent on clinical trial breakthroughs or anticipation of new drug approval. All these stocks named above have a much higher market valuation than IMUN. IMUN is currently valued at just $23 million which is peanuts in terms of valuation for a biotechnology company. Most are valued in the billions of dollars! If news hits of a major IMUN breakthrough in the treatment of cancer we could be in for a much bigger percentage run that any of the biotechnology stocks have experienced this year!
Make sure to keep a close eye on IMUN as Wall Street is just beginning to learn about this undiscovered biotechnology company.
Happy Trading,
AwesomeStocks.com
Follow Us On Twitter @AwesomeStocks (over 1,000,000 follow!)
Disclaimer
AwesomeStocks.com is owned and operated by Tribeca Investments Ltd. Tribeca Investments Ltd engaged in the business of advertising and promoting companies for monetary compensation. Any compensation received by Tribeca Investments Ltd constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Tribeca Investments Ltd. has been compensated up to $50,000 for IMUN investor relations services including this email by Winning Media. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of IMUN of which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. Tribeca Investments Ltd affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Tribeca Investments owns no shares of IMUN. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. AwesomeStock.com’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by AwesomeStocks.com or an offer or solicitation to buy or sell any security. Neither the owner of AwesomeStocks.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Any opinions expressed are subject to change without notice. AwesomeStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, through their website or is available from public sources and AwesomeStocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. AwesomeStocks.com does not independently investigate the information. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit www.AwesomeStocks.com. AwesomeStocks.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.
Market Data 
Markets 
AI
